Celldex Therapeutics (CLDX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Celldex Therapeutics (CLDX) over the last 14 years, with Q4 2024 value amounting to $23.5 million.
- Celldex Therapeutics' Accumulated Depreciation & Amortization rose 482.02% to $23.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.5 million, marking a year-over-year increase of 482.02%. This contributed to the annual value of $23.5 million for FY2024, which is 482.02% up from last year.
- Celldex Therapeutics' Accumulated Depreciation & Amortization amounted to $23.5 million in Q4 2024, which was up 482.02% from $22.4 million recorded in Q4 2023.
- In the past 5 years, Celldex Therapeutics' Accumulated Depreciation & Amortization registered a high of $23.5 million during Q4 2024, and its lowest value of $21.1 million during Q4 2021.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $21.6 million (2022), whereas its average is $22.0 million.
- In the last 5 years, Celldex Therapeutics' Accumulated Depreciation & Amortization plummeted by 2522.97% in 2020 and then surged by 482.02% in 2024.
- Celldex Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $21.2 million in 2020, then fell by 0.52% to $21.1 million in 2021, then increased by 2.37% to $21.6 million in 2022, then grew by 3.51% to $22.4 million in 2023, then rose by 4.82% to $23.5 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $23.5 million for Q4 2024, versus $22.4 million for Q4 2023 and $21.6 million for Q4 2022.